EC
Highly rated in
1
conditions
Highly rated in
1
conditions

Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

About Dr. Emile Calenda

Emile Calenda is in Rouen, France. Dr. Calenda is highly rated in 1 condition, according to our data. His top areas of expertise are Subconjunctival Hemorrhage, Retinal Artery Occlusion, and Amaurosis Fugax.

His clinical research consists of co-authoring 22 peer reviewed articles in the past 15 years.

Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Locations
  Rouen, FR
Background & Education
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


Save this doctor for later
Sign Up
Is this your doctor?
Find a second opinion
Find Now
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
Highly rated in
0
conditions
Centre Henri Becquerel
 
Rouen, FR 
 0.1 km
Herve Tilly is in Rouen, France. They have been an author on 253 peer reviewed articles and participated in 22 clinical trials in the past 15 years.
Highly rated in
0
conditions
Rouen University Hospital
 
Rouen, FR 
 0.1 km
Pascal Joly is in Rouen, France. They have been an author on 295 peer reviewed articles and participated in 65 clinical trials in the past 15 years.
Highly rated in
0
conditions
Centre Henri Becquerel
 
Rouen, FR 
 0.1 km
Fabrice Jardin is in Rouen, France. They have been an author on 195 peer reviewed articles and participated in 150 clinical trials in the past 15 years.